The present disclosure relates to a plurality of globular nanostructures, having a dispersity between 1 and 1.8 and a volume average hydrodynamic diameter of 13 nm to 90 nm; wherein each nanostructure comprises a polymer framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range of from 3.0 up to but not including 6.0; wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group independently being PO(OR.sup.1)(OR.sup.2); wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of a negative charge and H; and denotes an internal bond in the monomer residue. The present disclosure also relates to a method of producing such nanostructures, to the use of such nanostructures as well as to a pharmaceutical composition comprising such nanostructures.

The present disclosure relates to a plurality of globular nanostructures, having a dispersity between 1 and 1.8 and a volume average hydrodynamic diameter of 13 nm to 90 nm; wherein each nanostructure comprises a polymer framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range of from 3.0 up to but not including 6.0; wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group independently being PO(OR.sup.1)(OR.sup.2); wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of a negative charge and H; and denotes an internal bond in the monomer residue. The present disclosure also relates to a method of producing such nanostructures, to the use of such nanostructures as well as to a pharmaceutical composition comprising such nanostructures.

Compounds with magnetic properties are provided herein, which belong to the category of metal oxide nanoparticles, coated and conveniently functionalized, which are conjugated with naphthalene compounds related to agglomerates and -amyloid plaques present in neurodegenerative diseases. These new nanoparticles (NPs) are used for the non-invasive detection of agglomerates and amyloid plaques using the Magnetic Resonance Imaging (MRI) technique. The nanoparticles described here cross the blood-brain barrier (BBB), without the use of any membrane-disrupting agent. Likewise, they bind with high affinity and specificity to the agglomerates and -amyloid plaques, and are used as contrast agents in MRI for the early detection of Alzheimer's disease (AD).

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

This disclosure provides compositions of SALTAME core containing compounds and associated methods for use in tracking cells by magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and related methods.

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

A magnetic resonance imaging (MRI) T1 contrast agent composition including T1 contrast material coated on the surface of a nanoparticle support and an imaging method using the MRI T1 contrast agent. The MRI T1 contrast agent composition has excellent T1 spin magnetic relaxation effects by modifying the paramagnetic T1 contrast material on the nanoparticle support having a certain diameter such that the paramagnetic T1 contrast material has a certain thickness or less, and thereby remarkably increasing the surface-to-volume ratio of the T1 contrast material. The MRI T1 contrast agent provides more precise and clear T1 positive contrast images, and is thus useful for highly reliable image diagnosis.

The present description relates to an emulsion comprising an amphiphilic compound, a first phase comprising droplets including at least one perfluorocarbon compound and a second phase, which is aqueous. The droplets have a diameter d.sub.4,3 of between 0.5 pm and 5.5 pm, and the at least one perfluorocarbon compound has a boiling point above 100 C. The present description also relates to such an emulsion for use as an improving agent in ultrasound ablation surgery (FIG. 3).